Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

7.560 +0.470 (+6.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine Mindmed Inc

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Exposures Product Safety
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From MindMed
Via Business Wire
Analyst Expectations for Mind Medicine's Future
Via Benzinga
What 9 Analyst Ratings Have To Say About Mind Medicine
Via Benzinga
Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows
Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined... 
Via Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders,  
Via Benzinga
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Science Targeting Big Brains and Portfolios
Via AB Newswire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
MindMed to Participate at September Investor Conferences
From Mind Medicine (MindMed) Inc.
Via Business Wire
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative... 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
From Mind Medicine (MindMed) Inc.
Via Business Wire
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead
Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this: 
Via Benzinga
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
From Mind Medicine (MindMed) Inc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.